David Ketteridge

Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase

Paul Harmatz, Roberto Giugliani, Ida Vanessa Döederlein Schwartz et al. · Molecular Genetics and Metabolism · 2008 · 215 citations

Translational Medicine, Enzyme Replacement Therapy, Pathology +4

Direct Comparison of Measures of Endurance, Mobility, and Joint Function During Enzyme-Replacement Therapy of Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): Results After 48 Weeks in a Phase 2 Open-Label Clinical Study of Recombinant Human <i>N</i>-Acetylgalactosamine 4-Sulfatase

Paul Harmatz, David Ketteridge, Roberto Giugliani et al. · PEDIATRICS · 2005 · 213 citations

Clinical presentation and outcome in a series of 88 patients with the cblC defect

Sabine Fischer, Martina Huemer, Matthias R. Baumgartner et al. · Journal of Inherited Metabolic Disease · 2014 · 165 citations · Full text

Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Stuart J. Swiedler, Michael Beck, M Bajbouj et al. · American Journal of Medical Genetics Part A · 2005 · 161 citations

SURF1 deficiency: a multi-centre natural history study

Yehani Wedatilake, Ruth M. Brown, Robert McFarland et al. · Orphanet Journal of Rare Diseases · 2013 · 133 citations · Full text